Teva Pharmaceutical Industries (NYSE:TEVA) was upgraded by research analysts at Royal Bank of Canada from an “underperform” rating to a “sector perform” rating in a report released on Friday, MarketBeat.com reports. The brokerage presently has a $18.00 price target on the stock. Royal Bank of Canada’s price target points to a potential downside of 0.94% from the stock’s current price.
Several other brokerages have also issued reports on TEVA. Credit Suisse Group set a $20.00 target price on Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research report on Monday, January 22nd. Oppenheimer reissued a “hold” rating on shares of Teva Pharmaceutical Industries in a research report on Thursday. Cantor Fitzgerald set a $10.00 target price on Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research report on Monday, November 27th. Vetr lowered Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating and set a $22.63 target price for the company. in a research report on Thursday, January 11th. Finally, ValuEngine raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 11th. Nine research analysts have rated the stock with a sell rating, sixteen have given a hold rating and seven have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $21.46.
Shares of Teva Pharmaceutical Industries (NYSE:TEVA) traded down $0.47 during trading hours on Friday, hitting $18.17. The stock had a trading volume of 3,340,000 shares, compared to its average volume of 19,460,000. Teva Pharmaceutical Industries has a 12-month low of $10.85 and a 12-month high of $37.94. The company has a market cap of $18,840.00, a price-to-earnings ratio of -3.10, a P/E/G ratio of 1.51 and a beta of 0.59. The company has a debt-to-equity ratio of 1.20, a current ratio of 0.96 and a quick ratio of 0.66.
Hedge funds have recently added to or reduced their stakes in the company. Calton & Associates Inc. purchased a new position in shares of Teva Pharmaceutical Industries in the 4th quarter worth $108,000. Bank of Nova Scotia boosted its stake in shares of Teva Pharmaceutical Industries by 8.3% in the 2nd quarter. Bank of Nova Scotia now owns 6,903 shares of the company’s stock worth $229,000 after buying an additional 528 shares during the last quarter. Penserra Capital Management LLC purchased a new position in shares of Teva Pharmaceutical Industries in the 3rd quarter worth $129,000. Americafirst Capital Management LLC purchased a new position in shares of Teva Pharmaceutical Industries in the 2nd quarter worth $303,000. Finally, Fieldpoint Private Securities LLC purchased a new position in shares of Teva Pharmaceutical Industries in the 3rd quarter worth $171,000. Hedge funds and other institutional investors own 51.99% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This piece was originally posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece on another domain, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece can be accessed at https://sportsperspectives.com/2018/02/09/teva-pharmaceutical-industries-teva-upgraded-at-royal-bank-of-canada.html.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.